BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N, Rehman MU. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/3142306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Xu T, Tian H, Wu J, Yu X, Zeng L, Liu F, Liu Q, Huang X. Coxsackievirus Group B3 Has Oncolytic Activity against Colon Cancer through Gasdermin E-Mediated Pyroptosis. Cancers (Basel) 2022;14. [PMID: 36551691 DOI: 10.3390/cancers14246206] [Reference Citation Analysis]
2 Hu H, Xia Q, Hu J, Wang S. Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. J Clin Med 2022;11. [PMID: 36498574 DOI: 10.3390/jcm11236997] [Reference Citation Analysis]
3 Johnson A, Townsend M, O'Neill K. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. Cells 2022;11. [PMID: 36429054 DOI: 10.3390/cells11223626] [Reference Citation Analysis]
4 Liu X, Zhang J, Feng K, Wang S, Chen L, Niu S, Lu Q, Fang Y. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1023533] [Reference Citation Analysis]